Brachytherapy boost in combination with external beam radiation therapy (EBRT-BT) improves biochemical progression-free survival in patients with intermediate- and high-risk prostate cancer. However, its adoption in routine clinical practice remains uncertain. We aimed to evaluate national trends and factors associated with the use of EBRT-BT following the publication of the ASCENDE-RT trial.

Accurate applicator reconstruction is a critical step in 3D image-guided brachytherapy (3D-IGBT) for cervical cancer, directly influencing tumor control and organ-at-risk sparing. This systematic review evaluates the accuracy, efficiency, and clinical impact of applicator reconstruction methods, focusing on AI's potential to overcome existing limitations.

To evaluate the accuracy of the effective transit and dwell times for high-dose-rate (HDR) brachytherapy machines across multiple institutions. The aim was to establish reference levels for quality assurance (QA) in MicroSelectron and Flexitron afterloaders.

Cervical cancer remains a leading diagnosis among women in the state of Texas and manifests in a backdrop of health access and care inequities. In our study we aim to examine and highlight the geographic gaps in availability of brachytherapy across the state.

We analyzed the Nuclear Regulatory Commission event notifications related to brachytherapy events that occurred between January 1, 2005, and December 31, 2024. The events were categorized and their distribution and time evolution analyzed.

Three-dimensional (3D) interstitial brachytherapy (BT) can improve bulky cervical cancer treatment efficacy. BT technology guided by 3D-printed templates can assist radiation oncologists in accurately inserting needles and ensuring optimal dose coverage. Artificial intelligence (AI) holds promise for enhancing the accuracy, precision, efficiency, and overall quality of radiotherapy (RT) for cancer patients.

MRI is the standard imaging modality for contouring organs-at-risk and clinical target volume in cervical cancer brachytherapy, and is widely used along with CT for treatment planning and image guidance. However, MRI-CT fusion-based approach is time-consuming and error-prone as it requires two imaging sessions and image registration. To realize more efficient and streamlined MRI-guided workflow, we propose an automatic method for digitizing the applicator and catheters using MRI alone.

To identify MRI features associated with treatment failure in intermediate-risk prostate cancer patients treated with HDR brachytherapy monotherapy.

Brachytherapy-induced prostate edema (PE) can result in altered target dose coverage in prostate cancer patients treated with low-dose-rate (LDR) brachytherapy. While visualization of PE on CT is limited, PE is evident on magnetic resonance imaging (MRI) day 0 (D0) postimplant assessment, a critical step in the MRI-assisted radiosurgery (MARS) framework that improves LDR brachytherapy quality assurance. This study investigated PE in patients treated with MARS to analyze the effect on postimplant dosimetry and further optimize the treatment-planning process.

Vaginal recurrence of endometrial cancer can be salvaged by external beam radiotherapy and vaginal brachytherapy, but data on MRI-guided brachytherapy is limited. This study evaluated disease and toxicity outcomes of patients treated with MRI-guided brachytherapy for vaginal recurrence of endometrial cancer.

Calibration and quality control are fundamental to ensure that an accurate dose is delivered to a tumor, by HDR 192Ir radioactive sources in brachytherapy treatments. Consequently, it is essential for each radiation oncology center to implement a quality assurance program that includes an external audit. A cost-effective strategy, to meet the biannual requirements of licensing authorities, is the use of a well-established postal audit system employing phantoms and passive detectors.

To evaluate oncologic outcomes, prognostic factors, and toxicity associated with salvage brachytherapy in locally recurrent prostate cancer after radiotherapy and assess the role of next-generation imaging in early detection.

Design and develop an epoxy resin-based cylindrical phantom to simulate cancer treatment conditions in high dose rate (HDR) brachytherapy and evaluate the spatial dose distribution around a Ir source using an Sulfamic Acid/EPR system.

Mycosis fungoides (MF) is a highly radiosensitive tumor and low dose palliative radiotherapy is an essential treatment modality with excellent results. However, some skin sites with complex, oblique or very curved shape are difficult to treat with conventional radiotherapy techniques. We report our experience using HDR brachytherapy to treat MF in complex skin sites.

High-dose-rate interstitial brachytherapy (HDR-IBT) is commonly used for treating oral tongue squamous cell carcinoma (OTSCC). This study aims to evaluate long-term outcomes, survival predictors, chronic side effects, and failure patterns in patients receiving adjuvant HDR-IBT after surgical resection.

Optimizing radiotherapy delivery for higher-risk prostate cancer often requires dose escalation while minimizing dose to surrounding normal tissues. We report on the feasibility of combining high-dose-rate (HDR) brachytherapy with dose intensification to the dominant intra-prostatic lesion (DIL) followed by magnetic resonance-guided stereotactic body radiotherapy (MRgSBRT).

Several nonsurgical techniques are available for the management of inoperable primary and metastatic lung diseases. While Stereotactic body radiotherapy is a well-established technique, its access in low and middle-income countries (LMICs) is restricted. This study aims to present our experience on the feasibility of the high-dose-rate interstitial brachytherapy (IBT) in inoperable lung lesions, including technique and outcomes in LMICs.

The aim was to evaluate the toxicities and survival of patients with inoperable vulvar cancer treated using brachytherapy (BT).

We investigated baseline magnetic resonance imaging (MRI) radiomic features for predicting tumor response in patients with locally advanced cervical cancer (LACC) at brachytherapy (BT).